UK122 |
| Catalog No.GC63693 |
UK122는 IC50이 0.2μM인 강력하고 선택적인 유로키나제형 플라스미노겐 활성제(uPA) 억제제입니다. UK122는 조직형 PA(tPA), 플라스민, 트롬빈 및 트립신의 억제가 전혀 또는 거의 없음을 보여줍니다(모두 IC50>100μM). UK122, 4-oxazolidinone 유사체는 항암제이며 암세포의 이동과 침윤을 억제합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 940290-58-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion[1].
UK122 (11.1, 33.3, 100 μM; 24 h) dose-dependently inhibits cell migration and significantly reduces the invasiveness of CFPAC-1 cells[1]. UK122 (10-100 μM; 48 h) has no effect of any cell growth or cell morphology change in CFPAC-1 cells[1].
[1]. Ming Zhu, et al. Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther. 2007 Apr;6(4):1348-56.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *